Safety and efficacy of baricitinib at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexate
暂无分享,去创建一个
M. Genovese | E. Keystone | P. Taylor | S. Beattie | W. Macias | P. Berclaz | Terence Rooney | M. Luchi | E. Drescher | Chin H Lee | D. Schlichting | Rosanne Fidelus-Gort
[1] J. O’Shea,et al. Janus kinase inhibitors in autoimmune diseases , 2013, Annals of the rheumatic diseases.
[2] Tamas Koncz,et al. Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial , 2013, The Lancet.
[3] Steven M Holland,et al. JAKs and STATs in immunity, immunodeficiency, and cancer. , 2013, The New England journal of medicine.
[4] E. Lee,et al. Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. , 2012, The New England journal of medicine.
[5] J. Kremer,et al. Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. , 2012, The New England journal of medicine.
[6] J. Fridman,et al. Selective Inhibition of JAK1 and JAK2 Is Efficacious in Rodent Models of Arthritis: Preclinical Characterization of INCB028050 , 2010, The Journal of Immunology.
[7] P. V. van Riel,et al. The Disease Activity Score and the EULAR response criteria. , 2005, Clinical and experimental rheumatology.
[8] Tanja Stamm,et al. Remission and active disease in rheumatoid arthritis: defining criteria for disease activity states. , 2005, Arthritis and rheumatism.
[9] J. Smolen,et al. The Simplified Disease Activity Index (SDAI) and the Clinical Disease Activity Index (CDAI): a review of their usefulness and validity in rheumatoid arthritis. , 2005, Clinical and experimental rheumatology.
[10] J. Ware,et al. Determining minimally important changes in generic and disease-specific health-related quality of life questionnaires in clinical trials of rheumatoid arthritis. , 2000, Arthritis and rheumatism.
[11] P. van Riel,et al. Validation of rheumatoid arthritis improvement criteria that include simplified joint counts. , 1998, Arthritis and rheumatism.
[12] J J Anderson,et al. American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. , 1995, Arthritis and rheumatism.
[13] P. Tugwell,et al. Minimum important difference between patients with rheumatoid arthritis: the patient's perspective. , 1993, The Journal of rheumatology.
[14] F. Arnett. Revised criteria for the classification of rheumatoid arthritis. , 1990, Orthopedic nursing.
[15] M. Liang,et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. , 1988, Arthritis and rheumatism.
[16] J. Fridman,et al. Selective Inhibition of JAK 1 and JAK 2 Is Efficacious in Rodent Models of Arthritis : Preclinical Characterization of INCB 028050 , 2010 .
[17] W. Leonard,et al. Jaks and STATs: biological implications. , 1998, Annual review of immunology.
[18] F. Breedveld,et al. Validity and reliability of the twenty-eight-joint count for the assessment of rheumatoid arthritis activity. , 1995, Arthritis and rheumatism.